Protein C News and Research

RSS

Various aspects of consumer genetics to be discussed at 2nd Annual Consumer Genetics Conference

At the 2nd Annual Consumer Genetics Conference taking place in Boston from June 2-4 at the Hynes Convention Center, these issues will be addressed and preeminent leaders from varying areas of expertise will provide perspectives on these crucial topics that are shaping the way we approach clinical medicine and helping to improve patient outcomes.

29 May 2010

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

Nihal Altan-Bonnet, assistant professor of cell biology, Rutgers University in Newark, and her research team have made a significant new discovery about RNA viruses and how they replicate themselves.

29 May 2010

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

Scientists using tiny particles of genetic material to interfere in the replication process of the deadly Ebola virus have successfully prevented monkeys exposed to that virus from dying of hemorrhagic fever. The proof-of-concept study, published in this week's issue of The Lancet, suggests that such protection also should be possible in humans.

29 May 2010

Preimplantation Factor essential for pregnancy to succeed: Study

Researchers at Yale School of Medicine and their colleagues at the Society for the Investigation of Early Pregnancy have helped clarify the function of a unique protein called Preimplantation Factor, which is produced by healthy embryos to direct embryo attachment and help the mother adapt to pregnancy.

29 May 2010

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Bioheart, Inc., announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease. Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.

29 May 2010

Exposure in womb to BPA, DES increase offspring's risk of breast cancer

Exposure in the womb to chemicals like Bisphenol-A (BPA) and Diethylstilbestrol (DES) can increase an offspring's risk of breast cancer, researchers at Yale School of Medicine report in a study published in current issue of Hormones and Cancer, a journal of The Endocrine Society.

29 May 2010

Allergic reactions prevent people with allergic asthma from generating healthy immune response to influenza

New research from UT Southwestern Medical Center suggests that allergic reactions to pet dander, dust mites and mold may prevent people with allergic asthma from generating a healthy immune response to respiratory viruses such as influenza.

29 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

DFG approves establishment of twelve new CRCs

The Deutsche Forschungsgemeinschaft has approved the establishment of twelve new Collaborative Research Centres beginning 1 July 2010. This was decided by the responsible Grants Committee at its spring meeting in Bonn. The new CRCs will initially be funded for four years with a total of 112 million euros (including a 20% programme allowance for indirect project costs).

29 May 2010

Pancreatic cancer patients with circulating tumor cells tend to have worse outcomes: Study

Fox Chase Cancer Center investigators find that pancreatic cancer patients who have circulating tumor cells tend to have worse outcomes than patients without circulating tumor cells. Additionally, the team has uncovered evidence that not all circulating tumor cells are the same, and some may predict worse outcomes than others.

29 May 2010

Life Technologies acquires majority stake in Geneart

Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has concluded its tender offer and acquired a majority stake in Geneart AG, the global leader of the synthetic gene market segment. The combination of Geneart with Life Technologies' resources and commercial capabilities creates a well-capitalized synthetic biology company with advanced technology and production capabilities, providing products to fuel innovation in this emerging field.

28 May 2010

Novel imaging system helps visualize and monitor cellular immune responses of transplanted tissue in real time

A group of "color-coded" laboratory mice are providing researchers with a novel way of tracking T-cells, enabling them to visualize and monitor the cellular immune responses of transplanted tissue in real time. The new imaging system is described in the June issue of Nature Medicine, which appears on-line this week.

28 May 2010

Researchers see plectasin as promising lead compound for new antibiotics

An active compound from fungi and lower animals may well be suitable as an effective weapon against dangerous bacteria. We're talking about plectasin, a small protein molecule that can even destroy highly resistant bacteria . Researchers at the Universities of Bonn, Utrecht, Aalborg and of the Danish company Novozymes AS have shed light on how the substance does this.

28 May 2010

Infectious diseases specialist from Walter and Eliza Hall Institute receives Frank Fenner Award

Infectious diseases specialist Dr Marc Pellegrini from the Walter and Eliza Hall Institute will today receive the Frank Fenner Award from the Australasian Society for Infectious Diseases, recognising Dr Pellegrini's efforts to understand human responses to chronic infections.

28 May 2010

Discovery may pave way to help reduce health hazards

A discovery that may pave the way to helping reduce health hazards such as E. coli in water could also make chemicals and drugs such as insulin cheaper to produce and their production more environmentally friendly.

28 May 2010

Biomedical engineering professor receives Transition Career Development Award

Biomedical engineering professor David Zaharoff has been awarded a Transition Career Development Award by the National Cancer Institute to further his research on Interleukin-12, a powerful cytokine that shows great promise for therapeutic treatment of numerous types of cancer.

28 May 2010

Cardiac biomarkers help nephrologists manage fluid overload in dialysis patients: Study

Nephrologists must consider fluid overload effects when prescribing dialysis, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology. The fluid overload biomarker, N-terminal pro-brain-type natriuretic peptide, previously known as a "cardiac biomarker" in dialysis patients, is an important component of managing patients with kidney disease.

28 May 2010

Thermo Fisher Scientific to acquire Fermentas International for $260M

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that it has signed a definitive agreement to acquire Fermentas International Inc. - a manufacturer and global distributor of enzymes, reagents and kits for molecular and cellular biology research - for $260 million in cash, subject to a post-closing adjustment. With headquarters in Burlington, Ontario, and principal operations in Vilnius, Lithuania, Fermentas has approximately 500 employees.

From Thermo Fisher Scientific Inc. 28 May 2010

Individuals with poor oral hygiene at increased risk of heart disease

Individuals who have poor oral hygiene have an increased risk of heart disease compared to those who brush their teeth twice a day, finds research published today on BMJ.com.

28 May 2010

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Oregon Health & Science University is partnering with the University of Oregon and Harvard Medical School to expedite basic science research into new and existing drugs and compounds that may prevent the complications associated with Fanconi anemia, an inherited condition that can lead to bone marrow failure and cancer.

28 May 2010

Protein C News and Research

Various aspects of consumer genetics to be discussed at 2nd Annual Consumer Genetics Conference

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

Preimplantation Factor essential for pregnancy to succeed: Study

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Exposure in womb to BPA, DES increase offspring's risk of breast cancer

Allergic reactions prevent people with allergic asthma from generating healthy immune response to influenza

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

DFG approves establishment of twelve new CRCs

Pancreatic cancer patients with circulating tumor cells tend to have worse outcomes: Study

Life Technologies acquires majority stake in Geneart

Novel imaging system helps visualize and monitor cellular immune responses of transplanted tissue in real time

Researchers see plectasin as promising lead compound for new antibiotics

Infectious diseases specialist from Walter and Eliza Hall Institute receives Frank Fenner Award

Discovery may pave way to help reduce health hazards

Biomedical engineering professor receives Transition Career Development Award

Cardiac biomarkers help nephrologists manage fluid overload in dialysis patients: Study

Thermo Fisher Scientific to acquire Fermentas International for $260M

Individuals with poor oral hygiene at increased risk of heart disease

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News